D. Boral Capital lowered the firm’s price target on Avita Medical (RCEL) to $22 from $25 and keeps a Buy rating on the shares. The CFO of Avita informed D. Boral that the company has no plans to enter the chronic wounds market for the foreseeable future. As a result, the firm removed chronic wounds from its model and adjusted its acute wounds market share assumptions to align with the company’s published guidance. With limited resources, Avita is prioritizing areas where its product attributes can have the greatest impact, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical’s Growth Potential and Strategic Expansion: Analyst Josh Jennings Reiterates Buy Rating
- AVITA Medical Reports Transformative Year Amidst Challenges
- Avita Medical price target lowered to $11 from $12 at Piper Sandler
- AVITA Medical Reports Revenue Growth Amid New Product Approvals
- Avita Medical’s Strong Financial Performance and Promising Growth Justify Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue